Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | CA2 | P00918 | 6/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 5/20 | 0.39 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.37 |
| ▸ | FDPS | P14324 | 1/20 | 0.37 |
| ▸ | GPR84 | Q9NQS5 | 4/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9176733 | 1.00 | ALDH1A1 (0.46) | ALDH1A1TP53ACE2TSHRCA2 | |
| SCHEMBL1410439 | 0.93 | ACE2 (0.52) | ALDH1A1TP53ACE2TSHRCA2 | |
| SCHEMBL16201902 | 0.91 | ACE2 (0.55) | ALDH1A1TP53ACE2TSHRCA2 | |
| SCHEMBL1410858 | 0.91 | ACE2 (0.55) | ALDH1A1TP53ACE2TSHRCA2 | |
| SCHEMBL10608159 | 0.86 | — | — | |
| SCHEMBL1410639 | 0.86 | — | — | |
| SCHEMBL4826883 | 0.82 | BLM (0.52) | ALDH1A1CA1 | |
| SCHEMBL8589919 | 0.82 | BLM (0.52) | ALDH1A1CA1 | |
| SCHEMBL11481735 | 0.82 | ALDH1A1 (0.46) | ALDH1A1TP53ACE2TSHRCA1 | |
| SCHEMBL28716932 | 0.81 | ACE2 (0.47) | ACE2CA2MAPK1CA1SLC15A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230233593-A1 | ORALLY-BIOAVAILABLE NUCLEOSIDE ANALOGS | VenatoRx Pharmaceuticals, Inc. | 2023-07-27 | — | — | US | disclosed |
| US-11638715-B2 | Orally-bioavailable nucleoside analogs | VenatoRx Pharmaceuticals, Inc. (US) | 2023-05-02 | — | — | US | disclosed |
| US-9074021-B2 | Cellulose derivative, thermo-molding material, molded body and method for preparation thereof, and case for electric and electronic devices | FUJIFILM CORPORATION (JP) | 2015-07-07 | — | — | US | disclosed |
| US-9074020-B2 | Cellulose derivative, resin composition, molded body, method for preparation thereof, and case for electric and electronic device | FUJIFILM CORPORATION (JP) | 2015-07-07 | — | — | US | disclosed |
| CN-102471384-B | Cellulose derivative, resin composition, molded body, method for producing molded body, and housing for electric and electronic devices | FUJIFILM CORP | 2015-06-17 | — | — | CN | disclosed |
| CN-102471539-B | Cellulose derivative, thermoformed material, molded body, production method therefor, and casing for electrical and electronic equipment | FUJIFILM CORP | 2015-04-08 | — | — | CN | disclosed |
| EP-2465874-B1 | CELLULOSE DERIVATIVE, RESIN COMPOSITION, MOLDED ARTICLE AND PROCESS FOR PRODUCTION THEREOF, AND HOUSING FOR ELECTRIC AND ELECTRONIC DEVICE | FUJIFILM CORP (JP) | 2015-02-25 | — | — | EP | disclosed |
| EP-2465899-B1 | CELLULOSE DERIVATIVE, THERMOFORMED MATERIAL, MOLDED BODY, PRODUCTION METHOD THEREFOR, AND CASING FOR ELECTRICAL AND ELECTRONIC EQUIPMENT | FUJIFILM CORP (JP) | 2014-11-05 | — | — | EP | disclosed |
| EP-2295470-B1 | CELLULOSE DERIVATIVE AND PROCESS FOR PRODUCTION THEREOF, CELLULOSE RESIN COMPOSITION, MOLDED ARTICLE AND METHOD FOR PRODUCTION THEREOF, AND HOUSING FOR ELECTROCHEMICAL DEVICE | FUJIFILM CORP (JP) | 2014-06-18 | — | — | EP | disclosed |
| US-8580384-B2 | Dielectric materials and methods of preparation and use thereof | POLYERA CORPORATION (US) | 2013-11-12 | — | — | US | disclosed |
| EP-2465899-A1 | CELLULOSE DERIVATIVE, THERMOFORMED MATERIAL, MOLDED BODY, PRODUCTION METHOD THEREFOR, AND CASING FOR ELECTRICAL AND ELECTRONIC EQUIPMENT | FUJIFILM Corporation (JP) | 2012-06-20 | — | — | EP | disclosed |
| US-20120146468-A1 | CELLULOSE DERIVATIVE, RESIN COMPOSITION, MOLDED BODY, METHOD FOR PREPARATION THEREOF, AND CASE FOR ELECTRIC AND ELECTRONIC DEVICE | FUJIFILM CORPORATION (JP) | 2012-06-14 | — | — | US | disclosed |
| US-20110175089-A1 | Dielectric Materials and Methods of Preparation and Use Thereof | FLEXTERRA, INC. | 2011-07-21 | — | — | US | disclosed |
| WO-2011088343-A2 | DIELECTRIC MATERIALS AND METHODS OF PREPARATION AND USE THEREOF | POLYERA CORPORATION (US) | 2011-07-21 | — | — | WO | disclosed |
| US-20110098463-A1 | CELLULOSE DERIVATIVE AND METHOD FOR PRODUCING THE SAME, CELLULOSE RESIN COMPOSITION, MOLDED MATTER AND METHOD FOR MAKING THE SAME, AND ELECTRICAL AND ELECTRONIC EQUIPMENT HOUSING | FUJIFILM CORPORATION (JP) | 2011-04-28 | — | — | US | disclosed |
| EP-2295470-A1 | CELLULOSE DERIVATIVE AND PROCESS FOR PRODUCTION THEREOF, CELLULOSE RESIN COMPOSITION, MOLDED ARTICLE AND METHOD FOR PRODUCTION THEREOF, AND HOUSING FOR ELECTROCHEMICAL DEVICE | FUJIFILM Corporation (JP) | 2011-03-16 | — | — | EP | disclosed |
| EP-0227306-B1 | PEPTIDE IMMUNOSTIMULANTS | PFIZER INC. (US) | 1989-09-13 | — | — | EP | disclosed |
| US-4767743-A | ANTIINFECTION AGENTS | PFIZER INC. (US) | 1988-08-30 | — | — | US | disclosed |
| EP-0227306-A2 | Peptide immunostimulants | PFIZER INC. (US) | 1987-07-01 | — | — | EP | disclosed |
| US-3946054-A | PERFUMES, TOBACCO, FOOD FLAVORS | INTERNATIONAL FLAVORS & FRAGRANCES INC. (US) | 1976-03-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11638715-B2 | Orally-bioavailable nucleoside analogs | SLC29A2, SLC29A1, PNP | ALDH1A1 2219/4885TP53 2604/4885ACE2 8/4885 |
| US-20230233593-A1 | ORALLY-BIOAVAILABLE NUCLEOSIDE ANALOGS | SLC29A2, SLC29A1, PNP | ALDH1A1 2219/4885TP53 2604/4885ACE2 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.